| 05/18 | CORRECTING AND REPLACING : NANOBIOTIX Provides First Quarter Operational and Financial Upd.. | BU |
| 05/18 | NANOBIOTIX Provides First Quarter Operational and Financial Update | BU |
| 05/17 | NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022 | BU |
| 05/11 | NANOBIOTIX to Participate in Two Upcoming Investor Conferences | BU |
| 05/04 | NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022 | BU |
| 05/02 | New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022.. | BU |
| 04/11 | Nanobiotix's Radiotherapy-activated Combination Therapy Shows Improved Anti-tumor Immun.. | MT |
| 04/11 | NANOBOTIX : New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation v.. | PU |
| 04/11 | NANOBOTIX : New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation .. | BU |
| 04/11 | Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the .. | CI |
| 04/11 | NANOBIOTIX : Press Release, dated April 08, 2022 - Form 6-K | PU |
| 04/08 | NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 An.. | BU |
| 04/08 | NANOBIOTIX : Form 20-f/a | PU |
| 03/30 | NANOBIOTIX : Inside Information / Other news releases | PU |
| 03/30 | NANOBIOTIX : Provides Business Update and Reports Full Year 2021 Financial Results - Form .. | PU |
| 03/30 | Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2021 | CI |
| 03/30 | NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results | BU |
| 03/16 | NANOBIOTIX : to Announce Full Year 2021 Financial Results on March 30, 2022 - Form 6-K | PU |
| 03/16 | NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022 | BU |
| 02/10 | NANOBIOTIX : Inside Information / Other news releases | PU |
| 02/09 | Nanobiotix's Pancreatic Cancer Treatment Shows No Toxicity In Early-Stage Trial Patient | MT |
| 02/09 | NANOBIOTIX : Announces Publication of New Clinical Case Study Highlighting First Patient E.. | PU |
| 02/09 | Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient .. | BU |
| 02/09 | Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient .. | CI |
| 02/04 | NANOBIOTIX : OPERATING AND FINANCIAL REVIEW AND PROSPECTS - Form 6-K | PU |
| 01/26 | NANOBIOTIX : Announces Publication of New Preclinical Immunotherapy Data Showcasing the Co.. | PU |
| 01/26 | NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the C.. | BU |
| 01/26 | Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing .. | CI |
| 01/10 | NANOBIOTIX : Provides Corporate Update and Highlights Key 2022 Milestone Targets - Form 6-.. | PU |
| 01/10 | NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets | BU |
| 01/05 | Nanobiotix Enrolls First Patient In Late-Stage Trial For Head, Neck Cancer Treatment | MT |
| 01/05 | Nanobiotix Enrolls First Patient in Phase 3 Study of Head, Neck Cancer Treatment | MT |
| 01/05 | NANOBIOTIX : Announces First Patient Enrolled in NANORAY-312 Global Phase III Registration.. | PU |
| 01/05 | NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registratio.. | BU |
| 01/05 | Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Regist.. | CI |
| 01/04 | Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 202.. | BU |
| 2021 | NANOBIOTIX : to Present at the 4th Annual Evercore ISI HealthCONx Conference - Form 6-K | PU |
| 2021 | NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference | BU |
| 2021 | GLOBAL MARKETS LIVE : Rotschild, Adidas, Allianz, Apple, AstraZeneca... | |
| 2021 | Nanobiotix's Cancer Drug Shows Potential As Combination Therapy In Preclinical Study | MT |
| 2021 | NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkp.. | PU |
| 2021 | NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkp.. | BU |
| 2021 | Nanobiotix S.A. Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and C.. | CI |
| 2021 | GLOBAL MARKETS LIVE : Electronic Arts, Credit Suisse, Novartis, Merck, Tesla... | |
| 2021 | NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Confere.. | PU |
| 2021 | NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Confere.. | BU |
| 2021 | GLOBAL MARKETS LIVE : HSBC, PayPal, Tesla, Daimler, Intel... | |
| 2021 | NANOBIOTIX : Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Fra.. | PU |
| 2021 | NANOBIOTIX : Unveils First Survival Data From Head, Neck Cancer Treatment | MT |
| 2021 | NANOBIOTIX : Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Fra.. | BU |
| 2021 | NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Fr.. | CI |
| 2021 | NANOBIOTIX : Provides Third Quarter Operational and Financial Update - Form 6-K | PU |
| 2021 | NANOBIOTIX : Provides Third Quarter Operational and Financial Update | BU |
| 2021 | NANOBIOTIX : In accordance with Articles L.233-8 II of the French Commercial Code and 223-.. | PU |
| 2021 | NANOBIOTIX : to Present First Survival Data From Priority Head and Neck Cancer Program Amo.. | PU |
| 2021 | NANOBIOTIX : to Present First Survival Data From Priority Head and Neck Cancer Program Amo.. | BU |
| 2021 | GLOBAL MARKETS LIVE : Sanofi, ASML, Apple, United Airlines, Netflix... | |
| 2021 | NANOBIOTIX : Announces Red Journal Publication of Preclinical Data Showing Radioenhancer N.. | PU |
| 2021 | NANOBIOTIX : Announces Red Journal Publication of Preclinical Data Showing Radioenhancer N.. | BU |
| 2021 | Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenha.. | CI |
| 2021 | NANOBIOTIX : In accordance with Articles L.233-8 II of the French Commercial Code and 223-.. | PU |
| 2021 | NANOBIOTIX : LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Form 6-K) | PU |
| 2021 | NANOBIOTIX : PROVIDES BUSINESS UPDATE AND REPORTS FINANCIAL RESULTS FOR THE FIRST HALF OF .. | PU |
| 2021 | NANOBIOTIX S A : Provides Business Update and Reports Financial Results for the First Half.. | BU |
| 2021 | Nanobiotix S.A. Reports Earnings Results for the Half Year Ended June 30, 2021 | CI |
| 2021 | GLOBAL MARKETS LIVE : Airbus, Ford, Intel, Apple, PayPal... | |
| 2021 | NANOBIOTIX : TO PRESENT AT THE H.C. WAINWRIGHT 23rd ANNUAL GLOBAL INVESTMENT CONFERENCE (F.. | PU |
| 2021 | NANOBIOTIX S A : to Present at the H.C. Wainwright 23rd Annual Global Investment Conferenc.. | BU |
| 2021 | GLOBAL MARKETS LIVE : Netflix, Novartis, Tesla, Autodesk, AMC... | |
| 2021 | NANOBIOTIX : PROVIDES SECOND QUARTER OPERATIONAL AND FINANCIAL UPDATE (Form 6-K) | PU |
| 2021 | NANOBIOTIX S A : Provides Second Quarter Operational and Financial Update | BU |
| 2021 | GLOBAL MARKETS LIVE : Amazon, The Gap, Fod, Lockheed Martin, CureVac... | |
| 2021 | NANOBIOTIX : ANNOUNCES INITIATION OF NEW CLINICAL STUDY EVALUATING NBTXR3 IN LUNG CANCER (.. | PU |
| 2021 | NANOBIOTIX S A : Begins Early-Stage Study of Drug Candidate for Lung Cancer | MT |
| 2021 | NANOBIOTIX : Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer | BU |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
